Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIDIL vs ALAVERT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Loratadine is a selective inverse agonist of peripheral histamine H1 receptors, preventing histamine-mediated effects in allergic reactions.
Allergic rhinitis,Allergic conjunctivitis,Urticaria,Angioedema
Seasonal allergic rhinitis,Perennial allergic rhinitis,Chronic idiopathic urticaria
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
10 mg orally once daily; for PRN use, 10 mg orally every 4-6 hours as needed, not to exceed 24 mg/day.
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal elimination half-life of loratadine is 8–11 hours; its active metabolite desloratadine has a half-life of 17–24 hours. The longer half-life of desloratadine contributes to sustained antihistaminic effect.
Hepatic via CYP450 isoenzymes (primarily CYP3A4 and CYP2D6); undergoes N-demethylation and N-oxidation.
Primarily metabolized by CYP3A4 and CYP2D6 to active metabolite descarboethoxyloratadine.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Approximately 40% of the dose is excreted in urine (25% as unchanged drug and 15% as active metabolite desloratadine) and 40% in feces (as metabolites).
Approximately 90% bound to plasma proteins, primarily albumin.
Loratadine: 97–99% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). Desloratadine: 82–87% bound.
2.5-4.0 L/kg, indicating extensive tissue distribution.
Loratadine: approximately 120 L (1.7 L/kg for a 70 kg adult), indicating extensive tissue distribution. Desloratadine: 30–40 L/kg.
Oral bioavailability is approximately 50-60% due to first-pass metabolism.
Oral bioavailability is low (approximately 40–50%) due to extensive first-pass metabolism. Food increases bioavailability by 40% but does not affect clinical efficacy.
GFR 10-50 m L/min: 2.5 mg every 6-8 hours; GFR <10 m L/min: 2.5 mg every 8-12 hours.
For GFR 30-50 m L/min: 10 mg every 48 hours. For GFR <30 m L/min or on dialysis: avoid use or adjust to 10 mg every 72 hours with close monitoring.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: 10 mg every 48 hours. Child-Pugh C: avoid use or 10 mg every 72 hours.
Children 2-5 years: 1.25 mg orally every 4-6 hours (max 5 mg/day); Children 6-12 years: 1.25-2.5 mg every 4-6 hours (max 7.5 mg/day).
Age 6-11 years: 5 mg orally once daily; for PRN use, 5 mg every 4-6 hours, max 15 mg/day. Age ≥12 years: 10 mg orally once daily or 10 mg every 4-6 hours PRN, max 24 mg/day.
Initiate at 1.25 mg orally every 6-8 hours; maximum 5 mg per day due to increased risk of anticholinergic effects and renal impairment.
Initiate at 5 mg orally once daily; may increase to 10 mg once daily if tolerated and needed. Caution due to increased risk of anticholinergic effects and impaired renal function.
None
None.
May cause drowsiness and impair mental alertness,Avoid alcohol and other CNS depressants,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Elderly patients are more susceptible to anticholinergic effects
Avoid use in patients with severe hepatic impairment,Renal impairment may require dose adjustment,Caution in elderly patients due to increased anticholinergic sensitivity
Hypersensitivity to any component,Concurrent use with monoamine oxidase inhibitors
Hypersensitivity to loratadine or any component of the formulation
No specific food interactions, but taking with food may reduce GI side effects. Alcohol should be strictly avoided due to additive CNS depression. Grapefruit juice is not documented to interact.
Grapefruit juice may slightly increase loratadine absorption but not clinically significant. No specific dietary restrictions. Alcohol may increase CNS depression.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergic effects may cause neonatal tachycardia, irritability, and withdrawal symptoms if used near term.
ALAVERT (loratadine) is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but no adequate, well-controlled studies in pregnant women. Based on available human data, first trimester exposure does not show increased risk of major malformations. Second and third trimester risks are not established, but adverse fetal outcomes are unlikely given lack of placental transfer concerns.
Excretion into breast milk likely but negligible amounts; no adverse effects reported in infants. M/P ratio not established. Considered compatible with breastfeeding; monitor for sedation or irritability in neonate.
Loratadine is excreted into human breast milk. The milk-to-plasma ratio is approximately 1.17, with low relative infant dose (<2% of maternal weight-adjusted dose). Considered compatible with breastfeeding, but monitor infant for drowsiness or irritability. Caution in premature infants or those with renal impairment.
No specific dose adjustments required in pregnancy; however, use lowest effective dose due to potential anticholinergic effects. Pharmacokinetics may be altered (increased volume of distribution), but no dose adjustment recommended.
No dose adjustment is routinely recommended for pregnancy. Pharmacokinetic changes during pregnancy (increased volume of distribution, hepatic metabolism) are not significant enough to require dose changes for loratadine. Standard adult dose (10 mg once daily) can be used.
ACTIDIL (triprolidine) is a first-generation antihistamine with sedative properties. Use cautiously in elderly due to risk of confusion, urinary retention, and falls. Avoid in patients with narrow-angle glaucoma, BPH, or asthma. Administer with food if GI upset occurs. Onset of action is 30-60 minutes; duration 4-6 hours.
Alavert (loratadine) is a non-sedating antihistamine with minimal anticholinergic effects. Onset of action is within 1-3 hours; peak effect at 8-12 hours. Useful for chronic urticaria and allergic rhinitis. Does not cause significant QTc prolongation. Avoid in severe hepatic impairment (Child-Pugh C) without dose adjustment.
Do not drive or operate heavy machinery until you know how this medication affects you; it can cause drowsiness.,Avoid alcohol and other CNS depressants, as they may increase sedation.,Take exactly as prescribed; do not exceed recommended dose.,If you miss a dose, skip it; do not double the next dose.,Notify your doctor if you experience blurred vision, difficulty urinating, or severe drowsiness.,Do not use for prolonged periods without medical advice.
Take once daily at the same time, with or without food.,Do not exceed recommended dose to avoid side effects.,May cause mild drowsiness in some patients; avoid driving if affected.,Do not use for acute asthma attacks or lower respiratory symptoms.,Store at room temperature away from moisture and heat.,Notify your doctor if symptoms persist or worsen.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIDIL vs ALAVERT, answered by our medical review team.
ACTIDIL is a Antihistamine that works by H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.. ALAVERT is a Second-generation Antihistamine that works by Loratadine is a selective inverse agonist of peripheral histamine H1 receptors, preventing histamine-mediated effects in allergic reactions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIDIL and ALAVERT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIDIL is: 2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.. The standard adult dose of ALAVERT is: 10 mg orally once daily; for PRN use, 10 mg orally every 4-6 hours as needed, not to exceed 24 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIDIL and ALAVERT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIDIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergi. ALAVERT is classified as Category C. ALAVERT (loratadine) is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but no adequate, well-controlled studies in pregnant women. Based on ava. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.